Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Just before Pope Francis’ recent visit to Papua New Guinea, roadside stalls selling betel nut, a mild local intoxicant, were shut down. While this isn’t good for the many small stall holders ...

Novartis announced new data from the ALITHIOS open-label extension study. Data show first-line Kesimpta (ofatumumab) treatment for up to six years led to less disability and disease progression in ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

Prime Minister Anthony Albanese says the federal government is in the process of finalising a deal to expand the NRL to Papua New Guinea. Media reports suggest PNG will enter the NRL in 2028.

The FDA yesterday approved Novartis’ Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers, significantly expanding the number of patients who will ...

Novartis’s Pluvicto (lutetium vipivotide tetraxetan) was already approved in this setting in 2023 after positive results from its Phase III VISION trial. The majority of the results presented at ...